🚀 VC round data is live in beta, check it out!
Karolinska Development Valuation Multiples
Discover revenue and EBITDA valuation multiples for Karolinska Development and similar public comparables like Werewolf Therapeutics, Passage Bio, Mendus, NeuroSense Therapeutics and more.
Karolinska Development Overview
About Karolinska Development
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved, and commercializes the innovations through the sales of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.
Founded
2003
HQ
Employees
8
Website
Sectors
Financials (FY)
EV
$23M
Karolinska Development Stock Performance
Karolinska Development has current market cap of $29M, and enterprise value of $23M.
Karolinska Development's stock price is $0.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23M | $29M | (4.3%) | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKarolinska Development Valuation Multiples
Karolinska Development Financial Valuation Multiples
As of March 7, 2026, Karolinska Development has market cap of $29M and EV of $23M.
Equity research analysts estimate Karolinska Development's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29M | XXX | $29M | XXX | XXX | XXX |
| EV (current) | $23M | XXX | $23M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Karolinska Development Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Karolinska Development Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Werewolf Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Passage Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Mendus | XXX | XXX | XXX | XXX | XXX | XXX |
| NeuroSense Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Reviva Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Karolinska Development M&A Activity
Karolinska Development acquired XXX companies to date.
Last acquisition by Karolinska Development was on XXXXXXXX, XXXXX. Karolinska Development acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Karolinska Development
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKarolinska Development Investment Activity
Karolinska Development invested in XXX companies to date.
Karolinska Development made its latest investment on XXXXXXXX, XXXXX. Karolinska Development invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Karolinska Development
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Karolinska Development
| When was Karolinska Development founded? | Karolinska Development was founded in 2003. |
| Where is Karolinska Development headquartered? | Karolinska Development is headquartered in Sweden. |
| How many employees does Karolinska Development have? | As of today, Karolinska Development has over 8 employees. |
| Is Karolinska Development publicly listed? | Yes, Karolinska Development is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Karolinska Development? | Karolinska Development trades under KDEV ticker. |
| When did Karolinska Development go public? | Karolinska Development went public in 2011. |
| Who are competitors of Karolinska Development? | Karolinska Development main competitors are Werewolf Therapeutics, Passage Bio, Mendus, NeuroSense Therapeutics. |
| What is the current market cap of Karolinska Development? | Karolinska Development's current market cap is $29M. |
| Is Karolinska Development profitable? | No, Karolinska Development is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.